Legal Bay Pre-Settlement Funding Reports Pfizer Agrees to Settle Depo-Provera Birth Control Litigation
Pfizer has agreed to settle Depo-Provera birth-control litigation involving an estimated 5,000 claims worth more than $1.2 billion in aggregate, according to mass-tort funding company Legal Bay, with terms still confidential. The settlement adds a material legal overhang to Pfizer, whose FY2025 revenue was $62.6B and declined 1.6% year over year, but the ultimate earnings impact cannot yet be assessed.
What happened
Pfizer has agreed to settle Depo-Provera birth-control litigation involving an estimated 5,000 claims worth more than $1.2 billion in aggregate, according to mass-tort funding company Legal Bay, with terms still confidential.
The read · Aug 18
The reported Depo-Provera settlement moves the near-term risk to the downside for PFE, while confidential terms leave the earnings hit unquantified.
Wrong if
Pfizer confirmation could show limited net exposure, insurance coverage, or accounting treatment that makes the reported aggregate value less financially damaging than the headline implies.
CoverageSource: PR Newswire · Published here TUE, AUG 18 · 6:15 AM ET · the only report in this recordHow this is decided →
The chart · PFETradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
Legal Bay LLC, a pre-settlement funding company, reported that Pfizer agreed to resolve Depo-Provera birth-control litigation. The company estimates that approximately 5,000 claims could be covered by the settlement, with an aggregate value exceeding $1.2 billion. The report was issued on Aug. 18, 2026, and the settlement terms remain confidential.
The reported agreement directly affects Pfizer, which generated $62.6B of revenue in FY2025, down 1.6% year over year, with a 12.4% net margin and $1.36 diluted EPS. The disclosed claim estimate and aggregate value provide scale, but there is no information here on Pfizer's cash contribution, insurance recoveries, accounting treatment, or timing.
The next items to watch are confirmation from Pfizer or court filings, the final number of resolved claims, and disclosure of the settlement's financial terms. Until those details emerge, the legal headline is clearer than its effect on reported earnings or cash flow.
The read, in fullWhy it matters
The immediate pressure is legal-uncertainty expansion against a business already showing FY2025 revenue of $62.6B, down 1.6% year over year; a settlement exceeding $1.2 billion could weigh on cash flow or earnings once terms are disclosed. The read is limited by the absence of confirmed terms, insurance recoveries, and accounting treatment, so the setup is a headline-driven downside trade rather than a fully quantified fundamental break.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
Tactical / 1-2 weeks. Follow to be told when one lands.
▲ The case it holds
A settlement may cap the litigation overhang, and the confidential terms could ultimately show a manageable net cost relative to Pfizer's $62.6B FY2025 revenue.
▼ The case it breaks
The reported agreement covers approximately 5,000 claims with aggregate value exceeding $1.2 billion, adding a material legal liability to a company whose FY2025 revenue already fell 1.6% year over year.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →
PR NEWSWIRE / FILE